Venous Thromboembolism While on Anticoagulation With Apixaban

Venous thromboembolism (VTE) is a common condition whose pathophysiology is explained by Virchow’s triad with stasis, hypercoagulability, and endothelial injury. Direct oral anticoagulants (DOACs) showed non-inferiority when compared with conventional treatment using subcutaneous low molecular weigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazahreh, Farah, Habash, Fuad, López-Candales, Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218250/
https://www.ncbi.nlm.nih.gov/pubmed/34178510
http://dx.doi.org/10.7759/cureus.15189
_version_ 1783710731291590656
author Mazahreh, Farah
Habash, Fuad
López-Candales, Angel
author_facet Mazahreh, Farah
Habash, Fuad
López-Candales, Angel
author_sort Mazahreh, Farah
collection PubMed
description Venous thromboembolism (VTE) is a common condition whose pathophysiology is explained by Virchow’s triad with stasis, hypercoagulability, and endothelial injury. Direct oral anticoagulants (DOACs) showed non-inferiority when compared with conventional treatment using subcutaneous low molecular weight heparin (LMWH) and warfarin, but treatment failure is a concern and remains a challenge for physicians. In our case report, we present a patient who had VTE in the form of a saddle pulmonary embolus while on apixaban.
format Online
Article
Text
id pubmed-8218250
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82182502021-06-24 Venous Thromboembolism While on Anticoagulation With Apixaban Mazahreh, Farah Habash, Fuad López-Candales, Angel Cureus Cardiology Venous thromboembolism (VTE) is a common condition whose pathophysiology is explained by Virchow’s triad with stasis, hypercoagulability, and endothelial injury. Direct oral anticoagulants (DOACs) showed non-inferiority when compared with conventional treatment using subcutaneous low molecular weight heparin (LMWH) and warfarin, but treatment failure is a concern and remains a challenge for physicians. In our case report, we present a patient who had VTE in the form of a saddle pulmonary embolus while on apixaban. Cureus 2021-05-23 /pmc/articles/PMC8218250/ /pubmed/34178510 http://dx.doi.org/10.7759/cureus.15189 Text en Copyright © 2021, Mazahreh et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Mazahreh, Farah
Habash, Fuad
López-Candales, Angel
Venous Thromboembolism While on Anticoagulation With Apixaban
title Venous Thromboembolism While on Anticoagulation With Apixaban
title_full Venous Thromboembolism While on Anticoagulation With Apixaban
title_fullStr Venous Thromboembolism While on Anticoagulation With Apixaban
title_full_unstemmed Venous Thromboembolism While on Anticoagulation With Apixaban
title_short Venous Thromboembolism While on Anticoagulation With Apixaban
title_sort venous thromboembolism while on anticoagulation with apixaban
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218250/
https://www.ncbi.nlm.nih.gov/pubmed/34178510
http://dx.doi.org/10.7759/cureus.15189
work_keys_str_mv AT mazahrehfarah venousthromboembolismwhileonanticoagulationwithapixaban
AT habashfuad venousthromboembolismwhileonanticoagulationwithapixaban
AT lopezcandalesangel venousthromboembolismwhileonanticoagulationwithapixaban

Ejemplares similares